IDEXX Laboratories Expects 2024 Adjusted EPS Of $10.31-$10.59 Versus Prior Guidance Of $10.82-$11.20 And Consensus Of $11.06
Portfolio Pulse from Benzinga Newsdesk
IDEXX Laboratories has updated its 2024 financial outlook, lowering its adjusted EPS guidance to $10.31-$10.59 from the prior $10.82-$11.20 and below the consensus of $11.06. The company also revised its revenue, growth, and operating margin expectations downward, citing ongoing litigation and customer contract resolution payments as negative impacts.
August 06, 2024 | 10:36 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
IDEXX Laboratories has revised its 2024 financial outlook, lowering its adjusted EPS guidance to $10.31-$10.59 from the prior $10.82-$11.20 and below the consensus of $11.06. The company also adjusted its revenue, growth, and operating margin expectations downward, citing ongoing litigation and customer contract resolution payments as negative impacts.
The downward revision in EPS guidance and other key financial metrics indicates potential challenges for IDEXX Laboratories, likely leading to a negative short-term impact on its stock price. The ongoing litigation and customer contract resolution payments are significant factors contributing to this outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100